Results 171 to 180 of about 29,559 (188)
Some of the next articles are maybe not open access.
BioDrugs, 2002
Anakinra, a recombinant human interleukin-1 (IL-1) receptor antagonist, is the first biological agent approved to block the pro-inflammatory effects of IL-1 in patients with rheumatoid arthritis. In a double-blind, randomised trial in 472 patients with active, severe or very severe rheumatoid arthritis, recipients of subcutaneous anakinra 150 mg/day ...
Risto S, Cvetkovic, Gillian, Keating
openaire +2 more sources
Anakinra, a recombinant human interleukin-1 (IL-1) receptor antagonist, is the first biological agent approved to block the pro-inflammatory effects of IL-1 in patients with rheumatoid arthritis. In a double-blind, randomised trial in 472 patients with active, severe or very severe rheumatoid arthritis, recipients of subcutaneous anakinra 150 mg/day ...
Risto S, Cvetkovic, Gillian, Keating
openaire +2 more sources